Glycopyrronium bromide/formoterol
Combination medication
From Wikipedia, the free encyclopedia
Glycopyrronium bromide/formoterol, sold under the brand name Bevespi Aerosphere, is a combination medication used for the maintenance treatment of chronic obstructive pulmonary disease (COPD).[2][3] It is a combination of glycopyrronium bromide and formoterol. It is inhaled.[2][3]
| Combination of | |
|---|---|
| Glycopyrronium bromide | Muscarinic anticholinergic |
| Formoterol | Long-acting β2 agonist (LABA) |
| Clinical data | |
| Trade names | Bevespi Aerosphere |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | By mouth (inhalation) |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
The most common side effects include headache, nausea (feeling sick), muscle spasms and dizziness.[3]
Glycopyrronium bromide is a muscarinic receptor antagonist.[3] This means that it blocks muscarinic receptors (targets) in muscle cells in the lungs.[3] Because these receptors help control the contraction of muscles, when glycopyrronium is inhaled, it causes the muscles of the airways to relax, helping to keep the airways open.[3]
Formoterol is a long-acting beta-2 agonist.[3] It works by attaching to receptors known as beta-2 receptors found in the muscles of the airways.[3] When it attaches to these receptors, it causes the muscles to relax, which keeps the airways open.[3]
Medical uses
Glycopyrronium bromide/formoterol is indicated as a maintenance bronchodilator treatment to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD).[3]
